Lexaria Bioscience (LEXX) Other Non-Current Liabilities (2012 - 2021)
Lexaria Bioscience (LEXX) posted Other Non-Current Liabilities of $49989.0 for Q3 2021, down 44.08% sequentially from $89393.0 in Q3 2020, and down 44.08% YoY from $89393.0 in Q3 2020.
Lexaria Bioscience (LEXX) Other Non-Current Liabilities (2012 - 2021) Analysis & Trends
Lexaria Bioscience has reported Other Non-Current Liabilities for 5 years, with the latest figure at $49989.0 in Q3 2021.
- Quarterly Other Non-Current Liabilities fell 44.08% year-over-year to $49989.0 in Q3 2021, while the trailing twelve-month figure through Aug 2021 was $49989.0 (down 44.08% YoY) and the FY2021 annual result came in at $49989.0, down 44.08% from the prior year.
- Other Non-Current Liabilities slipped to $49989.0 in Q3 2021 per LEXX's latest filing, from $89393.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $89393.0 in Q3 2020 and troughed at $49989.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Aug 31, 2021 | 49,989.00 |
| Aug 31, 2020 | 89,393.00 |
| Jul 31, 2014 | 59,245.00 |
| Apr 30, 2014 | 59,245.00 |
| Jan 31, 2014 | 59,245.00 |
| Oct 31, 2013 | 59,245.00 |
| Jul 31, 2013 | 59,245.00 |
| Apr 30, 2013 | 59,245.00 |
| Jan 31, 2013 | 59,245.00 |
| Oct 31, 2012 | 59,245.00 |